Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars: The Unlikely Hero Of Specialty Pharma?

Executive Summary

In the patent cliff musical chairs game, the music has stopped and generic companies like Mylan and Teva are looking for the next growth driver. While this seems to be biosimilars, it appears that innovator companies who are used to developing biologics, are already sitting in their seats.

Advertisement

Related Content

Shire Exits Biosimilars, Streamlines Oncology Business
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Boehringer Ingelheim Throws Its Humira Biosimilar Hat Into The Ring
J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Stockwatch: Investors, Beware Of The False Positive
EU Demands Pfizer Offload Infliximab Biosimilar In Hospira Buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel